Tumour
Biology and Metastasis Team
Team Leader:
Dr Sue A Eccles
The major problem in cancer
therapy is the treatment of disease that has invaded normal tissues
and spread to secondary sites (metastasis). Our main aims are
to understand more about the molecular mechanisms of tumour progression,
and to develop better models to investigate the therapeutic potential
of novel agents for translation into the clinic. Many of the signalling
pathways and molecular processes used by tumour cells during invasion
are also utilised by endothelial cells during neoangiogenesis
(the process of development of new blood and lymphatic vessels
on which tumour growth and spread depends). Recognising key 'nodal
points' in these pathways will enable us to develop dual function
inhibitors which can target both tumour cells and activated endothelial
cells. Our work falls into two parts:
• Investigation
of signalling pathways in invasion and angiogenesis and their
potential as targets for therapy;
• Evaluation
of markers of metastatic potential (and organ site selectivity)
in human cancers.
We are also actively evaluating
the therapeutic activity of a wide range of molecular therapeutics
in in vitro and in vivo models relevant to human cancer.
Details
of our current research
programme are available in the searchable Projects Database.
|
 |
Staff
Contacts
Publications
Jobs
Centre
Structure
Target
Identification, Validation & Selection:
Development
of Preclinical Drug & Gene Therapy:
Clinical
Evaluation of New Treatments:
Last Modified
15/4/05
|